Borrelia Recurrentis InfectionBORRECURNCT07335965
Study of the Clinical, Microbiological and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the CNR Borrelia
An observational study of Borrelia Recurrentis Infection, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Recurrent borreliosis (RB) is a bacterial infection transmitted by ticks or lice. These infections occur in both temperate and tropical regions, but are rare in Australia and Antarctica. Read more about this study
- Who is it for?
- Ages 1 year and older
- Conditions the study is for
- Borrelia Recurrentis Infection
- How many people
- 25 participants
- Where
- 1 siteFrance
- Study dates
- 19 Feb 2025to 19 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Minor or adult subject having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg
Who may be able to join
- Minor or adult subject
- Having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg
Who cannot join
- Refusal to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Laboratoire de Bactériologie - CHU de Strasbourg - France
Strasbourg, 67091
Émilie TALAGRAND-REBOUL, MD, 33 3 69 55 14 57, emilie.talagrandreboul@chru-strasbourg.fr
Émilie TALAGRAND-REBOUL, MD
About this study
Official title: Study of the Clinical, Microbiological, and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the Borrelia National Reference Center
Recurrent borreliosis (RB) is a bacterial infection transmitted by ticks or lice. These infections occur in both temperate and tropical regions, but are rare in Australia and Antarctica. Due to climate change, the areas inhabited by the vectors of these infections are shifting, and the number of at-risk regions has significantly increased in recent years. More than twenty RB species have been described, responsible for variable clinical manifestations including fever, myalgia, digestive disorders, and sometimes neurological symptoms. Tick-borne RB represents a major public health problem, particularly in Africa. Mortality from these infections ranges from 5% to 10%. In recent years, diagnostic techniques have evolved. Microscopic diagnosis was initially the gold standard but had only moderate sensitivity and exhibited inter-operator variability. The advent of molecular biology now allows for increased sensitivity with excellent specificity and also enables the identification of the causative species.
A few cases have been described in France, consisting mainly of case reports. Therefore, this study will provide a comparative description, within a series, of cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, management, and patient outcomes.
- Conditions
- Borrelia Recurrentis Infection
- Keywords
- Borrelia Infections, Borrelia Recurrentis Infection
- Medical subject headings
- Relapsing Fever, Borrelia Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical and biological description of cases of recurrent imported borreliosis
This study does not include any evaluation, but simply describes cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, and treatment.
Measured: Up to 12 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start19 Feb 2025
- Primary completionOct 2026 (estimated)
- Study completion19 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Borrelia Recurrentis InfectionStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07335965
- Sponsor's protocol ID
- 9541
- Acronym
- BORRECUR
- Status last verified
- Jan 2026
- First submitted
- 2 Jan 2026
- Last updated
- 13 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Clinical, Microbiological, and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the Borrelia National Reference Center
- ClinicalTrials.gov ID
- NCT07335965
- Acronym / sponsor ID
- BORRECUR / 9541
- Conditions
- Borrelia Recurrentis Infection
- Keywords
- Borrelia Infections, Borrelia Recurrentis Infection
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 19 Feb 2025 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- 19 Oct 2026 (estimated)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recurrent borreliosis (RB) is a bacterial infection transmitted by ticks or lice. These infections occur in both temperate and tropical regions, but are rare in Australia and Antarctica. Due to climate change, the areas inhabited by the vectors of these infections are shifting, and the number of at-risk regions has significantly increased in recent years. More than twenty RB species have been described, responsible for variable clinical manifestations including fever, myalgia, digestive disorders, and sometimes neurological symptoms. Tick-borne RB represents a major public health problem, particularly in Africa. Mortality from these infections ranges from 5% to 10%. In recent years, diagnostic techniques have evolved. Microscopic diagnosis was initially the gold standard but had only moderate sensitivity and exhibited inter-operator variability. The advent of molecular biology now allows for increased sensitivity with excellent specificity and also enables the identification of the causative species.
A few cases have been described in France, consisting mainly of case reports. Therefore, this study will provide a comparative description, within a series, of cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, management, and patient outcomes.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 1 year and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Minor or adult subject having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg
Key inclusion criteria (2 listed)
- Minor or adult subject
- Having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg
Key exclusion criteria (1 listed)
- Refusal to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Clinical and biological description of cases of recurrent imported borreliosis
Time frame: Up to 12 years
This study does not include any evaluation, but simply describes cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, and treatment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Borrelia Recurrentis Infection, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Émilie TALAGRAND-REBOUL, MD (33 3 69 55 14 57, emilie.talagrandreboul@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical and biological description of cases of recurrent imported borreliosis (time frame: Up to 12 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.